Cheapest Wegovy Is It Safe UK Price - From £69.00

Our Pricing

Is Wegovy Safe? Clinical Evidence and UK Safety Profile

Many patients ask 'is Wegovy safe?' before starting treatment, and the clinical evidence provides reassuring answers. Wegovy (semaglutide 2.4mg) has been extensively studied in over 4,500 participants across the STEP clinical trial programme, demonstrating a well-established safety profile when used under medical supervision[1]. At Cured Pharmacy, our UK-registered prescribers assess every patient individually to ensure Wegovy is both safe and appropriate for their specific health circumstances.

Is Wegovy Safe? What Clinical Trials Tell Us

The question of whether Wegovy is safe has been rigorously examined through the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme. Across STEP 1-5 trials involving 4,567 adults with obesity or overweight, semaglutide 2.4mg demonstrated a consistent safety profile over 68 weeks of treatment[1]. The most common side effects were gastrointestinal in nature — nausea, diarrhoea, and constipation — typically mild to moderate and diminishing over time as the body adjusted to treatment.

Importantly, serious adverse events occurred at similar rates between Wegovy and placebo groups in these trials, suggesting the medication does not increase overall risk of serious complications when used appropriately[1]. The gradual dose escalation protocol built into Wegovy treatment (starting at 0.25mg and increasing over 16-20 weeks to the maintenance dose of 2.4mg) was specifically designed to minimise side effects and improve tolerability. This is why is Wegovy safe for most patients when prescribed and monitored by qualified healthcare professionals.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Wegovy in 2023 after thorough review of this safety data, and NICE (National Institute for Health and Care Excellence) has provided guidance on its use within the NHS for specific patient groups[2]. These regulatory approvals reflect confidence in Wegovy's safety profile when used according to prescribing guidelines.

Is Wegovy Safe for You? Individual Assessment Matters

While clinical trials demonstrate that Wegovy is safe for the majority of participants, individual suitability must always be assessed by a qualified prescriber. Certain medical conditions require careful consideration or may contraindicate Wegovy use entirely. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Wegovy due to potential thyroid risks identified in rodent studies[3].

Those with severe gastrointestinal disease, a history of pancreatitis, or diabetic retinopathy may require additional monitoring or alternative treatments. This is precisely why every patient at Cured Pharmacy completes a comprehensive clinical assessment before any prescription is issued — our UK-registered prescribers review your complete medical history, current medications, and individual risk factors to determine whether Wegovy is safe specifically for you.

Pre-Treatment Safety Screening

Our clinical assessment examines multiple safety factors: current BMI and weight loss goals, cardiovascular history, kidney and liver function, history of gallbladder disease, and any medications that might interact with semaglutide. This thorough screening process ensures that the question 'is Wegovy safe?' is answered individually for each patient, not just generally. Patients with well-controlled type 2 diabetes, for instance, may actually benefit from additional glycaemic improvements, but require adjusted diabetes medication to prevent hypoglycaemia[4].

Is Wegovy Safe Long-Term? Extended Use Evidence

Beyond the initial 68-week STEP trials, longer-term safety data has emerged from the SELECT cardiovascular outcomes trial, which followed over 17,000 participants for up to 5 years[5]. This landmark study not only confirmed that Wegovy is safe for extended use, but demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) compared to placebo in adults with established cardiovascular disease and overweight or obesity.

The SELECT trial's safety findings are particularly reassuring: rates of serious adverse events remained stable throughout the multi-year follow-up period, with no new safety signals emerging with prolonged exposure to semaglutide 2.4mg[5]. Gastrointestinal side effects, which are most common when starting treatment, typically resolved within the first few months and rarely led to treatment discontinuation in long-term users.

Ongoing Monitoring for Continued Safety

Even with established long-term safety data, responsible prescribing includes regular monitoring. At Cured Pharmacy, we recommend follow-up assessments every 3-6 months to review weight loss progress, assess tolerability, and check for any emerging concerns. This ongoing clinical oversight ensures that Wegovy remains safe and effective throughout your treatment journey, with dose adjustments or treatment changes made if needed.

Is Wegovy Safe Compared to Other Weight Loss Treatments?

When patients ask 'is Wegovy safe?', they often want to know how it compares to alternative treatments. Wegovy's safety profile compares favourably to many older weight loss medications that have been withdrawn from the market due to cardiovascular or psychiatric concerns. Unlike appetite suppressants such as phentermine, Wegovy does not increase heart rate or blood pressure — in fact, clinical trials showed modest reductions in both parameters[1].

Compared to orlistat (the most widely available non-prescription weight loss treatment in the UK), Wegovy demonstrates superior efficacy with a different side effect profile. While orlistat causes gastrointestinal effects related to fat malabsorption, Wegovy's GI effects stem from slowed gastric emptying and are typically more manageable with proper dose escalation. The key difference is that Wegovy requires medical supervision and prescription, ensuring safety is assessed before and monitored during treatment.

Is Wegovy Safe? Understanding Common Side Effects

To fully answer whether Wegovy is safe, patients need realistic expectations about potential side effects. In the STEP trials, approximately 74% of participants experienced at least one adverse event, though most were mild and transient[1]. Nausea affected approximately 44% of users (versus 18% on placebo), diarrhoea 30% (versus 16%), and constipation 24% (versus 11%). These gastrointestinal effects were most common during dose escalation and typically improved within 4-8 weeks.

Serious side effects are rare but require awareness. Acute pancreatitis occurred in 0.2% of Wegovy users in clinical trials, and acute gallbladder disease (cholecystitis or cholelithiasis) in approximately 1.6%[3]. These risks underscore why medical supervision is essential — prescribers can identify early warning signs and advise patients when to seek urgent medical attention. Symptoms such as severe persistent abdominal pain, especially if radiating to the back, warrant immediate clinical assessment.

Managing Side Effects Safely

Most patients find Wegovy is safe and tolerable when they follow practical strategies to minimise side effects: eating smaller, more frequent meals; avoiding high-fat foods that delay gastric emptying further; staying well-hydrated; and never advancing the dose faster than the prescribed schedule. Our clinical team provides detailed guidance on managing common side effects, and we're available to adjust treatment plans if tolerability becomes an issue. The goal is sustainable, safe weight loss — not pushing through intolerable symptoms.

Is Wegovy Safe at Cured Pharmacy? Our Clinical Standards

At Cured Pharmacy, ensuring Wegovy is safe for every patient begins with our rigorous clinical assessment process. Unlike some online providers, we never issue prescriptions without thorough medical review by UK-registered prescribers. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees clinical governance to ensure every prescription meets GPhC and MHRA standards for safe supply of prescription-only medicines.

We supply only genuine UK-licensed Wegovy from registered wholesalers, never grey-market or compounded alternatives that may carry additional safety risks. Every order includes comprehensive patient information leaflets, clear dosing instructions, and access to our clinical team for any questions or concerns during treatment. This commitment to pharmaceutical care means you can trust that Wegovy is safe when obtained through our registered pharmacy (GPhC 9012511), with all the regulatory protections that UK pharmacy registration provides.

Pricing transparency is part of our safety commitment — at £69.00 per month (with £20 off your first order using code Weightlossnew), you know exactly what you're paying before completing any assessment. There are no hidden fees, and our prescribers never feel pressure to approve unsuitable patients. The question 'is Wegovy safe?' is answered honestly for each individual, even if that means recommending an alternative treatment or additional medical review before starting.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
3. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 15 August 2026]
4. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., ... & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
5. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.